Germany’s BionNTech SE is laying off workers in Cambridge as part of a broader move to make "targeted adjustments to our U.S.

A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

When Özlem Türeci, co-founder of BioNTech, first heard about the novel coronavirus, she knew her company would have to work on a vaccine to fight it. American Amanda Anisimova upsets No. 1 Aryna ...

BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73. Please watch the video at Investors.com - What Are The Magnificent Seven Stocks?

Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.

Pfizer, BioNTech reach $1.95 billion covid-19 vaccine deal with U.S. government. The contract is the largest yet under the Trump administration’s Operation Warp Speed program, and will start ...

BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...

Before new versions of the Omicron strain took hold in the U.S., Pfizer Inc. and BioNTech SE had begun tinkering with their widely used Covid-19 vaccine. In May, researchers tracking how ...